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Abstract
Although changing a lymph node staging system from an anatomically based system to a
numerically based system in gastric cancer offers better prognostic performance, several
problems can arise: it does not offer information on the anatomical extent of disease and
cannot represent the extent of lymph node dissection. The purpose of this study was to dis-
cover an alternative lymph node staging system for gastric cancer. Data from 6025 patients
who underwent gastrectomy for primary gastric cancer between January 2000 and Decem-
ber 2010 were reviewed. The lymph node groups were reclassified into lesser-curvature,
greater-curvature, and extra-perigastric groups. Presence of any metastatic lymph node in
one group was considered positive. Lymph node groups were further stratified into four
(new N0–new N3) according to the number of positive lymph node groups. Survival out-
comes with this new N staging were compared with those of the current TNM system. For
validation, two centers in Japan (large center, n = 3443; medium center, n = 560) were
invited. Even among the same pN stages, the more advanced new N stage showed worse
prognosis, indicating that the anatomical extent of metastatic lymph nodes is important. The
prognostic performance of the new staging system was as good as that of the current TNM
system for overall advanced gastric cancer as well as lymph node—positive gastric cancer
(Harrell C-index was 0.799, 0.726, and 0.703 in current TNM and 0.799, 0.727, and 0.703 in
new TNM stage). Validation sets supported these outcomes. The new N staging system
demonstrated prognostic performance equal to that of the current TNM system and could
thus be used as an alternative.
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Introduction
In the field of gastric cancer, the fifth most common cancer and a major leading cause of can-
cer-related deaths worldwide [1] and particularly in East Asia [2,3], the application of appro-
priate staging systems has been a widely discussed issue in both Eastern and Western
countries. The current staging system for gastric cancer is based on the extent of the primary
tumor, the extent of lymph node (LN) metastasis, and the presence of distant metastases [4].
Although the staging for the extent of the primary tumor (T stage) is based on the depth of
tumor invasion into the gastric wall, the staging for the extent of LN metastasis (N stage) has
been converted from an anatomical location—based system to a numeric-based system [5,6].
Moreover, within this numeric-based system, the cutoff value of number of metastatic LNs
defining the pN category has been changed. The purpose of this conversion was to predict
prognosis more accurately [7–9] and to more easily perform comparisons with previous ana-
tomical-based classifications [10]. However, the numeric-based N staging system has limita-
tions, including its lack of information on the anatomical extent of the disease and its
discordance between preoperative and postoperative N staging [11], as there is no way to deter-
mine the number of metastatic LNs prior to an operation; furthermore, the system cannot rep-
resent the extent of LN dissection despite the use of radical LN dissection (D2) as standard
treatment [6,12,13].
The stomach is an organ to which blood is supplied by five main vessels (right and left gas-
troepiploic arteries, right and left gastric arteries, and short gastric artery); thus, it has an abun-
dant and complicated lymphatic network system[14]. This complexity of the lymphatic
network system for gastric cancer hinders the use of an anatomical-based system. However, the
anatomical location of metastatic LNs is nevertheless important, as their locations depend on
the location and severity of the primary cancer in the stomach; thus, it must be considered
when staging gastric cancer. Therefore, an alternative N staging system that can simply and
specifically represent the anatomic extent of the disease and provide accurate prognosis must
be developed. To this end, we reclassified the LNs near the stomach and proposed a new stag-
ing system for gastric cancer based on a new N category.
Methods
Study design and participants
The data from patients who underwent gastrectomy for primary gastric cancer at Yonsei Uni-
versity Hospital between January 2000 and December 2010 were reviewed. The Institutional
Review Board of Yonsei University Hospital agreed to exempt written informed consent from
the participants and approved this study (4-2012-0798). To validate the new staging system,
two hospitals in Japan were invited to participate in this study: one was the largest cancer cen-
ter in Japan, National Cancer Center (NCC) Hospital (January 2000 to December 2007), and
the other was a medium volume center, Tokyo University Hospital (TU; January 2004 to
December 2010).
Inclusion and exclusion criteria
All patients were pathologically confirmed to have primary gastric cancer. Minimally invasive
surgery, such as laparoscopic or robotic gastrectomy, was excluded, and patients with any dis-
tant metastases (including peritoneal seeding and para-aortic LN metastasis) were excluded.
Additional exclusion criteria were as follows: 1) cases in which the locations of LNs were not
divided, 2) patients who underwent preoperative chemotherapy, and 3) patients with meta-
static LNs of unclear locations. Ultimately, a total of 6025 patients were enrolled in this study
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and analyzed. In the validation sets, the criteria were identical for the NCC set (n = 3443), and
minimally invasive surgery was additionally included in the TU set (n = 560).
The extent of LN dissection and postoperative treatment
The surgical extent of LN dissection was based on the Japanese Classification of Gastric Carci-
noma [10]. The operator divided the location of each LN just after the operation, according to
the Japanese classification [6,10,15], and the pathologist reviewed and reported the status of each
LN. Adjuvant therapy was administered when a patient was diagnosed with at least stage II gas-
tric cancer, and the standard strategy of chemotherapy involved a 5-fluorouracil based regimen.
Classification of LN groups based on anatomical locations
LN groups could be divided roughly into perigastric LN groups and extra-perigastric (EP) LN
groups. Given the anatomical characteristics of the stomach, with lesser curvature (LC) and
greater curvature (GC) sides, we divided perigastric LNs into two groups: LC (1, 3, 5) and GC
(2, 4sa, 4sb, 4d, 6, and greater omentum). The remaining LNs, which were located in EP area
(except the para-aortic area) were classified as the EP group (Fig 1). Regardless of the number
of metastatic LNs, if any metastatic LN was involved in one group, we considered the corre-
sponding group to be positive for metastasis. Finally, we stratified the status of LN groups into
four categories: 1) new N0, indicated by no metastatic LN in any group; 2) new N1, indicated
by one positive LN among three groups (positive LC alone, positive GC alone, or positive EP
alone), regardless of number; 3) new N2, indicated by two positives out of three groups (posi-
tive LC + GC, positive LC + EP, or positive GC + EP), regardless of number; and 4) new N3,
defined as positive results for all three groups (LC + GC + EP).
A proposed new classification for the N staging system
To determine whether this new N classification could act as an N staging system, we compared
prognostic performances with those of the current pN staging system, the 7th edition of tumor-
node-metastasis (TNM) from UICC [16]. The new N classification was combined with the cur-
rent pT staging system, and a new TNM staging system was established. The new staging sys-
tem was compared with the results of the current TNM system, including substages.
Statistical analysis
A Kaplan-Meier analysis was performed to evaluate overall survival (OS). Survival data was
represented as patient mean survival as it was not always possible to calculate median survival.
The log-rank test and Cox proportional hazards model were used to compare the OS of the
new staging system and the current TNM staging system. Kappa values were applied to evalu-
ate the degree of conformity between the two staging systems. To compare the prognostic per-
formance of each staging system, the Harrell C-index [17] (measuring the predictive accuracy
of survival outcome) was used. A C-index of 1.0 indicated 100% predictive accuracy. In all
cases, a p-value of less than 0.05 was considered to be statistically significant. The statistical
analyses were performed using IBM SPSS 20.0 software (SPSS Inc., Chicago, IL, USA) and R
software version 2.15.2 with the “survival” package.
Results
Patient demographics
The mean age of enrolled patients was 57.6 ± 11.8 years, and 33.6% were female (Table 1). Of
6025 patients, 1387 (23.0%) underwent total gastrectomy, and the mean number of retrieved
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LNs was 40.7 ± 15.5. The distribution of pT stage was similar to recently published reports
[18–20]. The mean number of metastatic LNs was 3.2 ± 7.4 (8.5 ± 10.1 in lymph node—posi-
tive patients), and the median follow-up was 60 months.
Fig 1. Classification of lymph node groups based on anatomical location. Lesser curvature (LC) group (station number 1, 3, and 5, according to
Japanese classification), greater curvature (GC) group (station number 2, 4sa, 4sb, 4d, 6), and extra-perigastric (EP) group.
doi:10.1371/journal.pone.0149555.g001
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In validation sets, baseline characteristics were similar to the original set, except for the
extent of gastrectomy: pylorus-preserving or proximal gastrectomy cases were more frequently
performed in Japan. The median follow-up period was 77 months in the NCC set and 48
months in the TU set.
Characteristics of the new N classification
If the metastatic LN numbers were limited to only those near the perigastric area, the mean
number of metastatic LNs was 3.6 ± 3.6, and if this area was expanded to the EP area, the mean
number was 13.7 ± 11.9 (Table 2). The mean numbers of metastatic LNs according to the new
N classification were 2.2 ± 1.9, 6.7 ± 5.2, and 17.5 ± 12.2 in the new N1, new N2, and new N3
groups, respectively. The Kaplan-Meier curves of OS for each combination of the status-based
LN groups showed that the new classification provided a well-stratified prognosis for gastric
cancer (Fig 2A).
Comparison of survival among new N stages for each pN stage
The differences in patient survival among the new N stages according to pN stage (according
to 7th edition of the TNM [16]) are presented in Fig 2B, 2C, and 2D. When the numbers of met-
astatic LNs were one or two (pN1), the new N2 group had a poorer prognosis than the new N1
Table 1. Patient demographics and characteristics of gastric cancer.
Variables Yonsei (n = 6025) NCC (n = 3443) TU (n = 560)
Age (years), mean ± SD 57.6 ± 11.8 62.0 ± 11.6 65.6 ± 11.6
Sex
Male, n (%) 4002 (66.4%) 2346 (68.1%) 395 (70.5%)
Female, n (%) 2023 (33.6%) 1097 (31.9%) 165 (29.5%)
Extent of gastrectomy
Distal, n (%) 4633 (76.9%) 1649 (47.9%) 230 (41.1%)
Total, n (%) 1387 (23.0%) 809 (23.5%) 137 (24.4%)
†Others, n (%) 5 (0.1%) 985 (28.6%) 193 (34.5%)
pT stage
mucosa, n (%) 1641 (27.2%) 946(27.5%) 123 (22%)
submucosa, n (%) 1369 (22.7%) 1169(34.0%) 207 (37.0%)
proper muscle, n (%) 780 (12.9%) 378(11.0%) 59 (10.5%)
subserosa, n (%) 665 (11.0%) 455(13.2%) 92 (16.4%)
serosa, n (%) 1506 (25.0%) 464(13.4%) 75 (13.4%)
adjacent organ, n (%) 64 (1.1%) 31(0.9%) 3 (0.5%)
Number of metastatic LNs
Mean ± SD 3.2 ± 7.4 (8.5 ± 10.1)* 1.7±4.1(5.2±5.9)* 2.2 ± 6.1 (7.0 ± 9.3)*
0, n (%) 3794 (63.0%) 2326(67.6%) 386 (68.9%)
1–2, n (%) 716 (11.9%) 488(14.2%) 64 (11.4%)
3–6, n (%) 600 (10.0%) 335(9.7%) 51 (9.1%)
7–15, n (%) 541 (9.0%) 219(6.4%) 42 (7.5%)
16, n (%) 374 (6.2%) 75(2.2%) 17 (3.0%)
Retrieved LNs, mean ± SD 40.7 ± 15.5 43.0±72.9 38.4 ± 20.1
LN, lymph node; SD, standard deviation; NCC, National Cancer Center Hospital in Japan; TU, Tokyo University Hospital in Japan
*mean and SD of the number of metastatic LNs except pN0
† pylorus-preserving gastrectomy or proximal gastrectomy
doi:10.1371/journal.pone.0149555.t001
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group (Fig 2b) with statistical significance (p< 0.001). When the number of metastatic LNs
was between 3 and 6 (pN2), there was no significant difference between the new N1 and new
N2 groups; however, the prognosis of the new N3 group was worse than the new N2 group and
the new N1 group (Fig 2c; p = 0.045 and 0.011, respectively). For pN3 (metastatic LNs 7),
the prognosis of the new N3 group was worse than the new N1 and new N2 groups (Fig 2d;
p< 0.001 for both).
Relationship between the new staging system and the TNM 7th edition
system
The patient distributions of the new N classification and the pN staging system of the TNM 7th
edition are shown in Table 3. The kappa value between the pN stage of the TNM 7th edition
and new N classification systems was 0.803. In comparing the distributions of the new TNM
staging system (combined pT stage of TNM 7th edition with new N classification) and TNM
7th edition system, the kappa value was found to be 0.856. The number of patients in each stage
was well-distributed in both staging systems.
Comparison of prognostic performance between the new staging system
and the TNM 7th edition system
The hazard ratios (HRs) for pN1, pN2, and pN3, compared to pN0, were 2.5, 3.8, and 11.0,
respectively, in the current TNM 7th edition. In the new N classification, the HRs of new N1,
N2, and N3, compared to new N0, were 2.6, 5.3, and 11.2, respectively, which indicates that the
new N stage system shows a similar distribution to the current N staging system (Table 4).
The HRs of each TNM substage (Ib, IIa, IIb, IIIa, IIIb, and IIIc), which were compared to Ia,
were 2.1, 2.3, 4.5, 5.5, 9.3, and 19.3 in the current TNM 7th edition system and 1.9, 2.9, 4.1, 6.4,
11.0, and 20.2 in the new TNM staging system, respectively. In the validation sets, the distributions
of the HRs of each substage were similar between the new TNM stage and the TNM 7th edition.
According to the Kaplan-Meier curves, prognoses were well-stratified for each substage, not
only in the original set but also in the validation sets (Fig 3A to 3F). Harrell’s C-index, which
Table 2. Number of metastatic lymph nodes for each combination of the three status-based groups.
Number of patients (%) Mean metastatic LNs ± SD
Perigastric LN metastasis 1137 (18.9%) 3.6 ± 3.6
Extra-perigastric LN metastasis 1094 (18.1%) 13.7 ± 11.9
new N0 3794 (63.0%) 0
new N1 898 (14.9%) 2.2 ± 1.9
LC alone 407 (6.8%) 2.2 ± 1.8
GC alone 385 (6.4%) 2.3 ± 2.0
EP alone 106 (1.8%) 2.1 ± 1.8
new N2 583 (9.7%) 6.7 ± 5.2
LC + GC 345 (5.7%) 6.5 ± 4.8
LC + EP 124 (2.1%) 6.5 ± 4.8
GC + EP 114 (1.9%) 7.5 ± 6.4
new N3 750 (12.4%) 17.5 ± 12.2
LC + GC + EP 750 (12.4%) 17.5 ± 12.2
LN, lymph node; SD, standard deviation; LC, lesser-curvature group; GC, greater-curvature group; EP,
extra-perigastric group;
doi:10.1371/journal.pone.0149555.t002
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indicates prognostic performance, was 0.799 (95% CI: 0.792–0.806) and 0.799 (95% CI: 0.792–
0.806) in the TNM 7th edition and new TNM staging systems, respectively, and there was no
significant difference between the two (p> 0.999; Table 5). In addition, the C-index of the new
TNM staging system was comparable to that of the TNM 7th edition for advanced GC and LN-
positive GC (0.726 and 0.703 for TNM 7th edition vs. 0.727 and 0.703 for new TNM staging
system; p = 0.937 and 0.999, respectively). The results from NCC and TU validated the prog-
nostic performance of the new TNM staging system and were nearly identical to the current
TNM 7th edition system.
Discussion
The present results suggest that the more advanced new N stages were indicative of a worse
prognosis, even for the same current pN stage, implying that the anatomical extent of lymph
node metastasis is an important factor for gastric cancer prognosis and needs to be applied to
Fig 2. Overall survival for new N stages. A) patient survival among each combination of status-based lymph node groups, B) patient survival for each new
N stage at pN1 (number of metastatic lymph nodes: 1–2), C) patient survival for each new N stage at pN2 (number of metastatic lymph nodes: 3–6), D)
patient survival for each new N new stage at pN3 (number of metastatic lymph nodes 7). LC, lesser-curvature group; GC, greater-curvature group; EP;
extra-perigastric group.
doi:10.1371/journal.pone.0149555.g002
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gastric cancer staging systems. Accordingly, this new staging system, which reflects the ana-
tomical extent of lymph node metastasis, showed prognostic performance equal to that of the
current TNM staging system; moreover, these findings were validated by data from other cen-
ters in Japan, supporting this newly proposed staging system as a good alternative to the cur-
rent TNM staging system.
The most attractive point of our new stating system is its simplicity. With the new staging
system, the N stage depends only on the presence of metastatic LNs in each group (LC, GC,
and EP), regardless of the number of metastatic LNs. Counting the numbers of both retrieved
and metastatic LNs is affected by pathologists or pathology technicians who discover and
manipulate LNs in the resected specimens [21], which is one factor related to stage migration.
Although this problem can also affect the new staging system, we expect that this new system
could reduce any variations or errors in reporting and decrease stage migration, as counting all
of the LNs is not necessary. For example, if there is lymph node metastasis in each of the three
groups (LC, GC, and EP), it would be sufficient to access only three lymph nodes, one from
each group, rather than performing a whole lymphadenectomy. Furthermore, the new staging
system unifies preoperative and postoperative staging reports in gastric cancer. As it is difficult
to measure the presence and number of metastatic LNs preoperatively with current radiologic
tools [4,22,23], an anatomical-based staging system would be more appropriate than a numeric
N staging system, which requires counting all suspicious metastatic LNs preoperatively. Addi-
tionally, one suspicious metastatic LN in a preoperative image could in fact be more than one
metastatic LN. Accordingly, our staging system is not influenced by the number of metastatic
LNs and is only affected by the presence of a metastatic LN in at least one of three groups (LC,
GC, or EP). Thus, we expect that our newly proposed staging system would make preoperative
staging easier, particularly when there is an LN large enough to be detected, and this would
also mean that histological results would be those of the preoperative staging.
Another advantage of the new staging system is that it can represent the extent of LN dissec-
tion. After a long debate about the advantages of D2 LN dissection [24–28], it is currently con-
sidered to be the standard operative procedure in Asian countries [6] and is also recommended
Table 3. Patient distributions for the TNM 7th edition and new staging system.
TNM 7th edition
pN0 pN1 pN2 pN3 total
new N0 3794 0 0 0 3794
new N1 0 641 222 35 898
new N2 0 75 279 229 583
new N3 0 0 99 651 750
total 3794 716 600 915 6025
New staging system Ia Ib IIa IIb IIIa IIIb IIIc total
new Ia 2721 0 0 0 0 0 0 2721
new Ib 0 641 31 0 0 0 0 672
new IIa 0 23 433 54 6 0 0 516
new IIb 0 0 19 513 74 13 0 619
new IIIa 0 0 0 29 289 136 15 469
new IIIb 0 0 0 0 42 237 144 423
new IIIc 0 0 0 0 0 59 546 605
total 2721 664 483 596 411 445 705 6025
kappa value = 0.803 (between new N stage and pN 7th stage), 0.856 (between new TNM stage and TNM 7th stage)
doi:10.1371/journal.pone.0149555.t003
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in Western countries[12,13] for advanced gastric cancer. Nevertheless, the current numeric
staging system does not represent the extent of LN dissection in gastric cancer surgery, as D2
LN dissection is based on an anatomical perspective. Although the current TNM system rec-
ommends that at least 16 LNs should be evaluated pathologically [29], this number of LNs
does not guarantee a D2 LN dissection, as D1 LN dissection can occasionally be achieved for
more than 16 LNs and vice versa. By applying the new staging system, the extent of LN dissec-
tion is automatically reflected in the staging system, as EP LN dissection should be performed
when using the new N staging system.
The previous Japanese classification [10], which guided the anatomy-based treatment of
gastric cancer, provided direct surgical guidance [4] and the anatomic extent of disease neces-
sary to carefully assess gastric cancer [30]. In order to collect information on the anatomical
extent of LN involvement, each LN station should be identified and labeled before histopatho-
logical assessment. This procedure is typically performed after operation, as the en bloc removal
of lymph nodes is the most important oncological principle to be maintained during surgery.
For this reason, the identification and classification of LN stations could be subjective to arbi-
trary criteria depending on individual surgeons or pathologists. Therefore, the precise informa-
tion on LN status might be ambiguous, in particular for LN 7, 8a, 9, and 11p, and only
Table 4. Hazard ratios from Cox proportional hazardmodel andmean survival rates for the TNM 7th edition and the new staging system.
TNM 7th New staging system
HR p-value mean survival (months) HR p-value mean survival (months)
N0 1 - 135.7 (133.3–138.1) 1 - 135.7 (133.3–138.1)
N1 2.5 (2.1–3.0) < .001 109.9 (105.8–113.9) 2.6 (2.2–3.1) < .001 111.7 (107.7–115.6)
N2 3.8 (3.2–4.4) < .001 101.7 (95.4–107.9) 5.3 (4.6–6.2) < .001 89.4 (83.6–95.2)
N3 11.0 (9.7–12.4) < .001 55.4 (51.8–59.1) 11.2 (9.9–12.8) < .001 54.5 (50.4–58.5)
Ia 1 - 143.3 (141.1–145.5) 1 - 143.3 (141.1–145.5)
Yonsei Ib 2.1 (1.6–2.6) < .001 128.1 (123.7–132.4) 1.9 (1.5–2.5) < .001 129.2 (124.9–133.5)
IIa 2.3 (1.8–3.0) < .001 120.7 (116.1–125.2) 2.9 (2.3–3.6) < .001 116.4 (111.7–121.0)
IIb 4.5 (3.7–5.4) < .001 107.6 (102.9–112.3) 4.1 (3.4–5.1) < .001 109.9 (105.4–114.4)
IIIa 5.5 (4.5–6.8) < .001 98.4 (92.8–104.1) 6.4 (5.3–7.8) < .001 95.0 (89.2–100.7)
IIIb 9.3 (7.7–11.2) < .001 82.3 (75.6–88.9) 11.0 (9.1–13.2) < .001 76.2 (69.7–82.7)
IIIc 19.3 (16.5–22.7) < .001 49.3 (45.4–53.2) 20.2 (17.1–23.8) < .001 47.6 (43.5–51.7)
Ia 1 148.6(145.1–152.2) 1 148.6(145.1–152.2)
Ib 1.4(0.9–1.9) 0.096 147.1(143.5–151.6) 1.3(0.9–1.9) 0.112 148.1(144.0–152.1)
IIa 2.4(1.7–3.2) < .001 137.9(132.3–143.4) 2.4(1.8–3.3) < .001 136.3(130.5–142.2)
NCC IIb 3.1(2.3–4.1) < .001 129.5(123.3–135.8) 3.2(2.4–4.3) < .001 128.6(122.7–134.6)
IIIa 5.8(4.4–7.6) < .001 112.0(103.1–120.8) 5.8(4.4–7.6) < .001 111.7(103.0–120.3)
IIIb 7.6(5.7–10.0) < .001 100.4(90.4–110.4) 10.2(7.9–13.3) < .001 87.9(77.8–98.0)
IIIc 13.5(10.4–17.4) < .001 73.0(63.1–83.0) 13.3(10.1–17.7) < .001 73.5(61.7–85.3)
Ia 1 101.9 (98.6–105.2) 1 - 101.9 (98.6–105.2)
Ib 1.3 (0.5–3.8) 0.613 87.1 (79.7–94.4) 1.3 (0.5–3.8) 0.62 87.1 (79.7–94.4)
IIa 1.0 (0.3–2.8) 0.942 102.9 (96.3–109.6) 1.0 (0.3–2.8) 0.94 103.0 (96.5–109.6)
TU IIb 1.2 (0.4–3.4) 0.778 97.5 (90.1–105.0) 2.0 (0.9–4.5) 0.088 92.6 (84.4–100.9)
IIIa 4.3 (1.8–10.1) 0.001 80.9 (67.1–94.7) 3.8 (1.6–8.9) 0.002 79.2 (66.4–92.0)
IIIb 5.4 (2.6–11.3) < .001 70.7 (58.3–83.1) 5.2 (2.4–11.0) < .001 72.1 (59.8–84.5)
IIIc 7.4 (3.7–14.8) < .001 61.6 (47.7–75.5) 9.0 (4.3–19.1) < .001 55.3 (38.5–72.0)
NCC, National Cancer Center Hospital in Japan; TU, Tokyo University Hospital in Japan
doi:10.1371/journal.pone.0149555.t004
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Fig 3. Kaplan-Meier curves for overall survival of each staging system. A) TNM 7th edition system with substages in Yonsei set, B) new TNM staging
system with substages in Yonsei set, C) TNM 7th edition system with substages in NCC set, D) new TNM staging system with substages in NCC set, E) TNM
7th edition system with substages in TU set, F) new TNM staging system with substages in TU set. NCC, National Cancer Center in Japan; TU, Tokyo
University Hospital in Japan.
doi:10.1371/journal.pone.0149555.g003
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imperfect information may be available despite an increased level of complexity. With this pos-
sible reason among others, the Japanese classification system now uses a numeric-based N stag-
ing system that is divided into classification [15] and treatment guidelines [6]. Our new N
classification is based on the modified anatomical location of metastatic LNs, which can repre-
sent the anatomical extent of the disease. This new system could decrease the variations among
surgeons or pathologists while providing essential information on the extent of LN metastasis
by identifying the location of each LN group, as LC, GC, and EP classifications are unambigu-
ous. Consequently, it would facilitate accurate communication across institutions worldwide
regarding LN staging, as this novel concept is intuitive and easier to understand than the origi-
nal Japanese classification.
The main limitation of this study was that the present findings were not validated in a West-
ern population; rather, the outcomes were only from centers in East Asia. To generalize these
results, validation fromWestern countries is essential, as not only the epidemiology and treat-
ment strategies but also the biology of gastric cancer in Asian patients and Europeans are dif-
ferent [31–33]. Validation in a western population may give further insight into the potential
value of the new N staging system and perhaps allow global consolidation of LN staging in gas-
tric cancer.
Several alternative staging systems for estimating the extent of LN metastasis in gastric
cancer have been proposed, such as the LN ratio [34–38] (number of metastatic LNs / num-
ber of retrieved LNs) and the Kiel classification [39], which attempts to reflect biological
tumor properties. However, these proposed staging systems cannot actually solve the afore-
mentioned problems with the current TNM system, as they use the same numeric-based N
staging. Moreover, the LN ratio system was criticized for the arbitrarily determined cutoff
points, and the Kiel classification failed to be validated by recent studies from the same coun-
try [40]. Our novel LN staging system is intuitive and simple, can provide improved commu-
nication across institutions worldwide, can be used in preoperative staging, and can
represent the extent of LN dissection and the anatomical extent of the disease. Furthermore,
our results demonstrate that it offers substantial prognostic performance with validation.
This novel N staging system may be a useful alternative to current numeric-based staging sys-
tems for gastric cancer.
Table 5. The prognostic performance of each staging system (Harrell C-index) at each center.
TNM New TNM p-value
Overall
Yonsei 0.799(0.792–0.806) 0.799(0.792–0.806) >.9999
NCC 0.747(0.736–0.758) 0.748(0.737–0.759) 0.9487
TU 0.703(0.669–0.737) 0.701(0.667–0.735) 0.9668
AGC
Yonsei 0.726(0.717–0.735) 0.727(0.718–0.736) 0.9374
NCC 0.695(0.680–0.710) 0.700(0.685–0.715) 0.8137
TU 0.702(0.656–0.748) 0.698(0.652–0.744) 0.9510
LN positive
Yonsei 0.703(0.694–0.712) 0.703(0.694–0.712) >.9999
NCC 0.696(0.680–0.712) 0.701(0.685–0.717) 0.8251
TU 0.688(0.639–0.737) 0.682(0.634–0.730) 0.9303
NCC, National Cancer Center Hospital in Japan; TU, Tokyo University Hospital in Japan
doi:10.1371/journal.pone.0149555.t005
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Conclusion
Our novel N classification system for gastric cancer, which is based on modified anatomical
location, is simple, intuitive, reasonable, easy to apply in clinical practice, and could improve
communication among gastric cancer teams and centers. Application of our system may
resolve the inherent problems of current numeric N staging systems. Accordingly, we suggest
that our staging system may be a good alternative for gastric cancer staging.
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